Jump to content


LLS Highlighted in Dana-Farber Cancer Institute Newsletter

Posted by DrLouDeGennaro , 15 July 2014 · 1,806 views

I am very pleased to share that LLS is the lead feature story on the front page of Dana-Farber Cancer Institute’s summer 2014 newsletter, Impact.

The newsletter highlights organizations and individuals whose support of research is making an impact in the fight against cancer.

The article focuses on LLS’s awarding of eight new grants to Dana-Farber researchers totaling more than $8.5 million and part of a $19.3 million commitment made by LLS to blood cancer research at this institution.

One of the researchers, Irene Ghobrial, M.D., is the recipient of LLS’s prestigious Specialized Center of Research (SCOR) award, a five-year grant supporting the team’s understanding of the molecular basis of the progression from less to more severe blood cancers. In particular, they are seeking the genetic drivers that cause the progression of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) to acute myeloid leukemia (AML).

In addition, the team is studying the genetic drivers that cause the disease monoclonal gammopathy of undetermined significance (MGUS) to develop into multiple myeloma (MM). By understanding the progression of these diseases, it may be possible to identify therapies targeted to the pre-AML and pre-MM states. Ghobrial is also leading LLS’s initiative to create a network of clinical trial sites in community oncology settings as part of LLS’s Therapy Acceleration Program.

Other researchers mentioned in the article include David Weinstock, M.D., an LLS Scholar working on characterizing gene alterations that promote the growth of follicular lymphoma and Koshi Akahane, M.D., Ph.D, a LLS Fellow studying T cell acute lymphoblastic leukemia. Ami Bhat, M.D., Ph.D, Gianluca Varetti, Ph.D., and Haojian Zhang, Ph.D, are all Fellow award recipients; John Koreth, MD, Ph.D., and Kimberly Stegmaier, M.D. received Scholar awards. These career development awards reflect LLS’s commitment to support for the next generation of blood cancer researchers and is especially important in this period of decline in federal research funding.

Funding research in academic centers is vital to LLS’s cures and access agenda, and helps us in our quest to help save more lives.

Attached Image

or Sign In